Kelonia Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Boston, Massachusetts, United StatesWebsite
www.keloniatx.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
2
1
1
1
About Kelonia Therapeutics
Founded in 2017, Kelonia Therapeutics is a biotechnology company with a focus on vivo gene delivery. The company has headquarters in Boston, MA.Explore more
Kelonia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kelonia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Kelonia Therapeutics launches new products
Kelonia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Kelonia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Kelonia Therapeutics recently announced quarterly report
Check out if Kelonia Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Kelonia Therapeutics
Funding: Get notified immidiatlly once Kelonia Therapeutics has new funding data
Click to see if Kelonia Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Kelonia Therapeutics
Compare insights from companies similar to Kelonia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$56.1M
2021
Company Profile Activity
Activity Insights
Kelonia Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kelonia Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kelonia Therapeutics.
Kelonia Therapeutics financials insights
Gather financial insights about Kelonia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$50M
Kelonia Therapeutics Tech Stack
A closer look at the technologies used by Kelonia Therapeutics
Most Recent Scoops
Hiring Plans
Kelonia Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months with an increased focus that include Gene Therapy, and experience with Biotechnology, Clinical Trial Development, Health Sciences, Clinical Program Development, Hematology, and Clinical Trial Protocols.
Hiring Plans
Open Position
Open Position
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Kelonia Therapeutics News & Media
Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase In Years
Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus on cancer treatment, in a deal valued at up to $7 billion in cash.Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones, the Journal added, citing people.Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific conferences – the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, taking place on May 7-11, 2024, in Baltimore, Maryland, and the Protein Engineering Summit (PEGS) Boston Summit 2024, taking place on MKelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma
BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. KLN-1010, a novel, in vivo CAR-T cell therapy candidate for the treatment of multiple myeloma, which leverages the company’s in vivo Gene Placement System (iGPS®) technology, demonstrated that it is sa
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kelonia Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, Kelonia Therapeutics is a biotechnology company with a focus on vivo gene delivery. The company has headquarters in Boston, MA.... Read More
